Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD)

Benutzer: Gast

Dokumenttyp:: Zeitschriftenaufsatz
Autor(en):: Wolff, Andreas W. ; Bidner, Helen ; Remane, Yvonne ; Zimmer, Janine ; Aarsland, Dag ; Rascol, Olivier ; Wyse, Richard K. ; Hapfelmeier, Alexander ; Lingor, Paul
Titel:: Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD)
Stichworte:: Aging Neuroscience ; Parkinson's disease ; clinical trial ; safety ; tolerability ; symptomatic efficacy ; disease modification ; Fasudil ; ROCK inhibition
Zeitschriftentitel:: Frontiers in Aging Neuroscience
Jahr:: 2024
Band / Volume:: 16
Volltext / DOI:: doi:10.3389/fnagi.2024.1308577
Verlag / Institution:: Frontiers Media S.A.
E-ISSN:: 1663-4365
Publikationsdatum:: 14.02.2024
CC-Lizenz:: by, https://creativecommons.org/licenses/by/4.0

BibTeX

Vorkommen: